Molecule Details
| InChIKey | SNFVHLQYHFQOEP-UHFFFAOYSA-N |
|---|---|
| Compound Name | Afimetoran |
| Canonical SMILES | Cc1c(-c2[nH]c3ccc(C4CCN(CC(N)=O)CC4)cc3c2C(C)C)cn2ncnc2c1C |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 3 |
| Pfam Stratification | Cross-Family |
| Avg pChEMBL | 8.07 |
| Source | ChEMBL;BindingDB |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB16580 |
|---|---|
| Drug Name | Afimetoran |
| CAS Number | 2171019-55-7 |
| Groups | investigational |
| ATC Codes | nan |
| Description | Afimetoran is an immunomodulator and an antagonist of toll-like receptors 7 and 8.[L32018, L32023] It is also is under investigation in clinical trial NCT04269356 (Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986256 in Healthy Male Participants). |
Cross-references: BindingDB: 273241